Switch to:
Also traded in: Argentina, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.82
BMY's Cash-to-Debt is ranked lower than
62% of the 859 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.03 vs. BMY: 0.82 )
Ranked among companies with meaningful Cash-to-Debt only.
BMY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.32  Med: 0.95 Max: 3.88
Current: 0.82
0.32
3.88
Equity-to-Asset 0.38
BMY's Equity-to-Asset is ranked lower than
81% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. BMY: 0.38 )
Ranked among companies with meaningful Equity-to-Asset only.
BMY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.46 Max: 0.64
Current: 0.38
0.33
0.64
Debt-to-Equity 0.60
BMY's Debt-to-Equity is ranked lower than
69% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. BMY: 0.60 )
Ranked among companies with meaningful Debt-to-Equity only.
BMY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.08  Med: 0.42 Max: 1.01
Current: 0.6
0.08
1.01
Debt-to-EBITDA 1.46
BMY's Debt-to-EBITDA is ranked higher than
57% of the 495 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.92 vs. BMY: 1.46 )
Ranked among companies with meaningful Debt-to-EBITDA only.
BMY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.71  Med: 1.22 Max: 2.57
Current: 1.46
0.71
2.57
Interest Coverage 17.77
BMY's Interest Coverage is ranked lower than
63% of the 648 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 86.08 vs. BMY: 17.77 )
Ranked among companies with meaningful Interest Coverage only.
BMY' s Interest Coverage Range Over the Past 10 Years
Min: 8.44  Med: 19.6 Max: 45.77
Current: 17.77
8.44
45.77
Piotroski F-Score: 6
Altman Z-Score: 5.57
Beneish M-Score: -3.24
WACC vs ROIC
9.19%
2.23%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 15.63
BMY's Operating Margin % is ranked higher than
75% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.97 vs. BMY: 15.63 )
Ranked among companies with meaningful Operating Margin % only.
BMY' s Operating Margin % Range Over the Past 10 Years
Min: 10.45  Med: 22.84 Max: 31.24
Current: 15.63
10.45
31.24
Net Margin % 1.74
BMY's Net Margin % is ranked lower than
63% of the 802 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.32 vs. BMY: 1.74 )
Ranked among companies with meaningful Net Margin % only.
BMY' s Net Margin % Range Over the Past 10 Years
Min: 4.85  Med: 15.78 Max: 56.42
Current: 1.74
4.85
56.42
ROE % 2.83
BMY's ROE % is ranked lower than
59% of the 832 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.94 vs. BMY: 2.83 )
Ranked among companies with meaningful ROE % only.
BMY' s ROE % Range Over the Past 10 Years
Min: 7.21  Med: 19.06 Max: 78.36
Current: 2.83
7.21
78.36
ROA % 1.13
BMY's ROA % is ranked lower than
58% of the 871 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.88 vs. BMY: 1.13 )
Ranked among companies with meaningful ROA % only.
BMY' s ROA % Range Over the Past 10 Years
Min: 2.99  Med: 8.44 Max: 35.08
Current: 1.13
2.99
35.08
ROC (Joel Greenblatt) % 87.00
BMY's ROC (Joel Greenblatt) % is ranked higher than
95% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.23 vs. BMY: 87.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BMY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 51.19  Med: 94.31 Max: 155.17
Current: 87
51.19
155.17
3-Year Revenue Growth Rate 9.80
BMY's 3-Year Revenue Growth Rate is ranked higher than
65% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. BMY: 9.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BMY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -8.4  Med: 3.1 Max: 11.8
Current: 9.8
-8.4
11.8
3-Year EBITDA Growth Rate 26.50
BMY's 3-Year EBITDA Growth Rate is ranked higher than
80% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. BMY: 26.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BMY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -26  Med: 7.8 Max: 26.5
Current: 26.5
-26
26.5
3-Year EPS without NRI Growth Rate -20.20
BMY's 3-Year EPS without NRI Growth Rate is ranked lower than
84% of the 663 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. BMY: -20.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BMY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -22.9  Med: 5.4 Max: 30.7
Current: -20.2
-22.9
30.7
GuruFocus has detected 3 Warning Signs with Bristol-Myers Squibb Company BMY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BMY's 30-Y Financials

Financials (Next Earnings Date: 2018-10-26)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

BMY Guru Trades in Q3 2017

Pioneer Investments 1,338,444 sh (+1560.72%)
First Eagle Investment 49,229 sh (+334.54%)
Paul Tudor Jones 124,964 sh (+51.68%)
Joel Greenblatt 121,594 sh (+39.03%)
Louis Moore Bacon 142,025 sh (+28.16%)
Frank Sands 17,324 sh (+3.28%)
PRIMECAP Management 6,374,900 sh (+0.95%)
Mario Gabelli 467,867 sh (+0.38%)
Murray Stahl 49,015 sh (+0.05%)
Tom Gayner 10,000 sh (unchged)
Jeff Auxier 6,393 sh (unchged)
Ray Dalio Sold Out
Caxton Associates Sold Out
Ronald Muhlenkamp 177,169 sh (-0.45%)
Ken Fisher 504,493 sh (-0.50%)
Mairs and Power 339,845 sh (-0.93%)
Dodge & Cox 29,054,961 sh (-1.77%)
Kahn Brothers 19,050 sh (-2.72%)
Vanguard Health Care Fund 50,693,892 sh (-5.50%)
Manning & Napier Advisors, Inc 1,884,716 sh (-7.37%)
T Rowe Price Equity Income Fund 3,165,000 sh (-13.77%)
Jim Simons 10,846,600 sh (-19.58%)
Steven Cohen 75,000 sh (-25.00%)
Signature Select Canadian Fund 71,350 sh (-39.92%)
Eaton Vance Worldwide Health Sciences Fund 597,663 sh (-7.37%)
» More
Q4 2017

BMY Guru Trades in Q4 2017

Jeremy Grantham 10,700 sh (New)
Pioneer Investments 2,797,167 sh (+108.99%)
Steven Cohen 115,000 sh (+53.33%)
Louis Moore Bacon 192,140 sh (+35.29%)
Jim Simons 14,302,900 sh (+31.87%)
Joel Greenblatt 154,793 sh (+27.30%)
Ken Fisher 582,213 sh (+15.41%)
PRIMECAP Management 6,557,578 sh (+2.87%)
Dodge & Cox 29,106,111 sh (+0.18%)
Kahn Brothers 19,050 sh (unchged)
First Eagle Investment 49,229 sh (unchged)
Tom Gayner 10,000 sh (unchged)
Jeff Auxier 6,393 sh (unchged)
Frank Sands Sold Out
Murray Stahl 48,915 sh (-0.20%)
Ronald Muhlenkamp 174,575 sh (-1.46%)
Mairs and Power 332,592 sh (-2.13%)
T Rowe Price Equity Income Fund 3,040,000 sh (-3.95%)
Vanguard Health Care Fund 48,534,812 sh (-4.26%)
Mario Gabelli 408,602 sh (-12.67%)
Paul Tudor Jones 29,786 sh (-76.16%)
Eaton Vance Worldwide Health Sciences Fund 565,824 sh (-5.33%)
» More
Q1 2018

BMY Guru Trades in Q1 2018

John Hussman 25,000 sh (New)
Leon Cooperman 468,000 sh (New)
Caxton Associates 4,572 sh (New)
PRIMECAP Management 16,430,950 sh (+150.56%)
Paul Tudor Jones 68,575 sh (+130.23%)
Jeff Auxier 7,393 sh (+15.64%)
Mario Gabelli 466,179 sh (+14.09%)
Kahn Brothers 19,750 sh (+3.67%)
Ronald Muhlenkamp 178,436 sh (+2.21%)
Jim Simons 14,528,300 sh (+1.58%)
Tom Gayner 10,000 sh (unchged)
Jeremy Grantham 10,700 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 565,824 sh (unchged)
First Eagle Investment Sold Out
Signature Select Canadian Fund Sold Out
Ken Fisher 577,081 sh (-0.88%)
Pioneer Investments 2,742,824 sh (-1.94%)
Murray Stahl 47,115 sh (-3.68%)
Vanguard Health Care Fund 46,688,361 sh (-3.80%)
Dodge & Cox 27,817,611 sh (-4.43%)
Louis Moore Bacon 178,083 sh (-7.32%)
T Rowe Price Equity Income Fund 2,770,000 sh (-8.88%)
Mairs and Power 291,902 sh (-12.23%)
Steven Cohen 75,000 sh (-34.78%)
Joel Greenblatt 23,077 sh (-85.09%)
» More
Q2 2018

BMY Guru Trades in Q2 2018

Ray Dalio 273,634 sh (New)
Steven Cohen 3,416,898 sh (+4455.86%)
Joel Greenblatt 296,301 sh (+1183.97%)
Paul Tudor Jones 86,718 sh (+26.46%)
Mario Gabelli 556,603 sh (+19.40%)
Dodge & Cox 32,705,086 sh (+17.57%)
PRIMECAP Management 18,043,794 sh (+9.82%)
Vanguard Health Care Fund 50,597,061 sh (+8.37%)
T Rowe Price Equity Income Fund 2,810,000 sh (+1.44%)
Kahn Brothers 19,950 sh (+1.01%)
Ken Fisher 581,310 sh (+0.73%)
John Hussman 25,000 sh (unchged)
Jeremy Grantham 10,700 sh (unchged)
Tom Gayner Sold Out
Ronald Muhlenkamp Sold Out
Louis Moore Bacon Sold Out
Leon Cooperman Sold Out
Caxton Associates Sold Out
Jeff Auxier 7,269 sh (-1.68%)
Pioneer Investments 2,682,994 sh (-2.18%)
Murray Stahl 45,900 sh (-2.58%)
Mairs and Power 278,944 sh (-4.44%)
Jim Simons 10,547,200 sh (-27.40%)
Eaton Vance Worldwide Health Sciences Fund 176,060 sh (-68.88%)
» More
» Details

Insider Trades

Latest Guru Trades with BMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2018-06-30 Add 8.37%0.49%$50.53 - $62.98 $ 60.8913%50,597,061
Dodge & Cox 2018-06-30 Add 17.57%0.22%$50.53 - $62.98 $ 60.8913%32,705,086
T Rowe Price Equity Income Fund 2018-06-30 Add 1.44%0.01%$50.53 - $62.98 $ 60.8913%2,810,000
Ken Fisher 2018-06-30 Add 0.73%$50.53 - $62.98 $ 60.8913%581,310
Mario Gabelli 2018-06-30 Add 19.40%0.03%$50.53 - $62.98 $ 60.8913%556,603
Joel Greenblatt 2018-06-30 Add 1183.97%0.22%$50.53 - $62.98 $ 60.8913%296,301
Kahn Brothers 2018-06-30 Add 1.01%$50.53 - $62.98 $ 60.8913%19,950
Tom Gayner 2018-06-30 Sold Out 0.01%$50.53 - $62.98 $ 60.8913%0
Ronald Muhlenkamp 2018-06-30 Sold Out 4.09%$50.53 - $62.98 $ 60.8913%0
Leon Cooperman 2018-06-30 Sold Out 1.11%$50.53 - $62.98 $ 60.8913%0
Vanguard Health Care Fund 2018-03-31 Reduce -3.80%0.25%$59.92 - $68.98 $ 60.89-5%46,688,361
Dodge & Cox 2018-03-31 Reduce -4.43%0.06%$59.92 - $68.98 $ 60.89-5%27,817,611
T Rowe Price Equity Income Fund 2018-03-31 Reduce -8.88%0.08%$59.92 - $68.98 $ 60.89-5%2,770,000
Ken Fisher 2018-03-31 Reduce -0.88%$59.92 - $68.98 $ 60.89-5%577,081
Leon Cooperman 2018-03-31 New Buy1.11%$59.92 - $68.98 $ 60.89-5%468,000
Mario Gabelli 2018-03-31 Add 14.09%0.02%$59.92 - $68.98 $ 60.89-5%466,179
Ronald Muhlenkamp 2018-03-31 Add 2.21%0.09%$59.92 - $68.98 $ 60.89-5%178,436
Joel Greenblatt 2018-03-31 Reduce -85.09%0.12%$59.92 - $68.98 $ 60.89-5%23,077
Kahn Brothers 2018-03-31 Add 3.67%0.01%$59.92 - $68.98 $ 60.89-5%19,750
First Eagle Investment 2018-03-31 Sold Out 0.01%$59.92 - $68.98 $ 60.89-5%0
Vanguard Health Care Fund 2017-12-31 Reduce -4.26%0.3%$59.94 - $65.35 $ 60.89-3%48,534,812
Dodge & Cox 2017-12-31 Add 0.18%$59.94 - $65.35 $ 60.89-3%29,106,111
T Rowe Price Equity Income Fund 2017-12-31 Reduce -3.95%0.04%$59.94 - $65.35 $ 60.89-3%3,040,000
Ken Fisher 2017-12-31 Add 15.41%0.01%$59.94 - $65.35 $ 60.89-3%582,213
Mario Gabelli 2017-12-31 Reduce -12.67%0.02%$59.94 - $65.35 $ 60.89-3%408,602
Ronald Muhlenkamp 2017-12-31 Reduce -1.46%0.05%$59.94 - $65.35 $ 60.89-3%174,575
Joel Greenblatt 2017-12-31 Add 27.30%0.03%$59.94 - $65.35 $ 60.89-3%154,793
Vanguard Health Care Fund 2017-09-30 Reduce -5.50%0.35%$54.24 - $63.74 $ 60.894%50,693,892
Dodge & Cox 2017-09-30 Reduce -1.77%0.02%$54.24 - $63.74 $ 60.894%29,054,961
T Rowe Price Equity Income Fund 2017-09-30 Reduce -13.77%0.13%$54.24 - $63.74 $ 60.894%3,165,000
Ken Fisher 2017-09-30 Reduce -0.50%$54.24 - $63.74 $ 60.894%504,493
Mario Gabelli 2017-09-30 Add 0.38%$54.24 - $63.74 $ 60.894%467,867
Ronald Muhlenkamp 2017-09-30 Reduce -0.45%0.01%$54.24 - $63.74 $ 60.894%177,169
Joel Greenblatt 2017-09-30 Add 39.03%0.03%$54.24 - $63.74 $ 60.894%121,594
First Eagle Investment 2017-09-30 Add 334.54%0.01%$54.24 - $63.74 $ 60.894%49,229
Kahn Brothers 2017-09-30 Reduce -2.72%$54.24 - $63.74 $ 60.894%19,050
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Bristol-Myers Squibb Company

SymbolPriceYieldDescription
BMYMP.PFD999.900.20$2.00 Convertible Preferred Stock

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:LSE:AZN, NYSE:LLY, XPAR:SAN, LSE:GSK, XTER:BAYN, TSE:4503, TSE:4519, TSE:4578, TSE:4568, HKSE:01093, NYSE:ABBV, TSE:4151, TSE:4528, NYSE:MRK, SHSE:600436, SHSE:600867, SZSE:002422, MIL:REC, BOM:500087, BOM:500302 » details
Traded in other countries:BMY.Argentina, BMYB34.Brazil, BRM.Germany, BMY.Mexico, BMY.Switzerland, 0R1F.UK,
Headquarter Location:USA
Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals products. The company operates in one segment that is Biopharmaceuticals.

Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded drugs.

Guru Investment Theses on Bristol-Myers Squibb Company

Bill Nygren Comments on Bristol-Myers Squibb - Jul 13, 2018

Bristol-Myers Squibb (NYSE:BMY) is a global biopharmaceutical company with leading franchises in oncology, immunoscience and cardiovascular drugs. Long-time shareholders may recall a successful Bristol-Myers Squibb investment that we sold in 2013. We got another opportunity to own this company during the past quarter when investors became fearful that a competing drug would take share in the cancer market. We believe these fears are overstated because cancer remains a dangerous disease that is difficult to treat. The company’s two most valuable drugs Opdivo and Yervoy should continue to grow revenue as they maintain effectiveness with new tumor types. Bristol Myers Squibb also has the most new molecular agents and the highest number of combinations of agents in trials. Moreover, the company’s R&D and marketing prowess also make it a desired partner for promising academic and small biotech innovators. Collectively, these assets should assure Bristol-Myers Squibb’s oncology leadership for many years. We believe intrinsic value is closer to the $70 level it traded for earlier this year than its more recent price in the low $50s.



From Bill Nygren (Trades, Portfolio)'s Oakmark Fund second-quarter shareholder letter.

Check out Bill Nygren latest stock trades

Baron Funds' Fifth Avenue Growth Fund Comments on Bristol-Myers Squibb Company - Feb 13, 2017

Bristol-Myers Squibb Company (NYSE:BMY) is a leading developer in Immuno-Oncology, the new wave of therapeutics aimed at displacing chemotherapeutics in cancer care with both improved efficacy (measured via survival outcomes) and safety profiles. While the class as a whole represents a success for society, the race for class dominance is heated and has proven to be difficult to predict. Coming into mid-2016, Bristol was the clear leader. The company squandered this lead in July when a widely anticipated clinical trial whose outcome was expected to read out positively, failed. While few question the drug’s efficacy, statistics and poor clinical trial design submarined Bristol and allowed competitor Merck to take the pole position commercially. Given the dire need for this patient population, the FDA granted Merck a pathway to market by the first half of this year that will give Merck at least a one year commercial advantage in time to market versus its competition. As a result, we decided to exit our investment in Bristol. While Merck has become the consensus leader, we think that their combination employs the wrong science approach and that Bristol is one of two players (AstraZeneca, the other) that will have an opportunity to ultimately come out on top given its strategy of combining two immune-therapeutics. We intend to follow the situation closely while looking for a more appropriate time to potentially get back into the investment.



From Baron Funds' Fifth Avenue Growth Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Dodge & Cox Comments on Bristol-Myers Squibb - Feb 01, 2017

Once a diversified pharmaceutical company facing significant patent expirations (a “cliff”), Bristol-Myers (NYSE:BMY) has transitioned into a focused biopharmaceutical company that is positioned to grow. Many of its competitors responded to their patent cliffs by expanding into other non-drug areas; Bristol-Myers shed its interests in those assets unrelated to the drug business (e.g., medical supply, nutritionals), focused on specialty drugs, and concentrated on only those therapeutic areas that it believed could be profitable over the long term. Its medicines help millions of people fight against such diseases as cancer, cardiovascular disease, hepatitis, HIV/ AIDS, and rheumatoid arthritis.



In 2016, one of Bristol-Myers’ lead immuno-oncology trials (CheckMate-026) failed and its stock price declined significantly. We think this is a short-term setback, and believe the company’s immuno-oncology business is particularly attractive with its strong pipeline of other drugs, significant growth potential, and reasonable valuation at 20 times forward earnings. After weighing the risks versus the long-term opportunities, we initiated a position in Bristol-Myers, which accounted for 1.3% of the Fund on December 31.





From Dodge & Cox's Stock Fund 2016 shareholder letter.



Check out Dodge & Cox latest stock trades

Baron Funds Comments on Bristol-Myers Squibb Co. - Oct 25, 2016

Bristol-Myers Squibb Company (NYSE:BMY) is a large diversified pharmaceutical company that is one of the leaders in the development of immune-system-stimulating therapies to fight cancer. These efforts are spearheaded by its product Opdivo, now approved to treat several types of cancer. After positive data was released on a rival drug to treat first-line advanced non-small-cell lung cancer, Bristol-Myers revealed that Opdivo did not meet the primary endpoint in a Phase III trial in the same indication, and its shares fell. We have exited our Bristol-Myers position, but are continuing to research the budding immuno-oncology space carefully. (Josh Riegelhaupt)







From Baron Opportunity Fund third-quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Bristol-Myers Squibb Company

Ray Dalio’s Top 6 Buys in 2nd Quarter Author of best-seller 'Principles' discloses top buys for the June quarter
Ray Dalio (Trades, Portfolio), author of best-seller “Principles,” disclosed on Tuesday that his $165 billion hedge fund’s top six buys for the second quarter were Cummins Inc. (NYSE:CMI), Applied Materials Inc. (NASDAQ:AMAT), Alibaba Group Holding Ltd. (NYSE:BABA), Bristol-Meyers Squibb Co. (NYSE:BMY), Walmart Inc. (NYSE:WMT) and Johnson & Johnson (NYSE:JNJ). Read more...
Ronald Muhlenkamp Dumps One Pharmaceutical Company in Favor of Another Guru releases 2nd-quarter portfolio
Ronald Muhlenkamp (Trades, Portfolio), leader of investment firm Muhlenkamp & Co. Inc., disclosed in his second-quarter portfolio that he exchanged his Bristol-Myers Squibb Co. (NYSE:BMY) holding for a position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ). Read more...
Report: Developing Opportunities within Cytosorbents, Nasdaq, Mastercard, Maxim Integrated Products, Bristol-Myers Squibb, and Equity Lifestyle Properties — Future Expectations, Projections Moving into 2018
Kahn Brothers’ High-Conviction Stock Picks for 2nd Quarter Legendary investor Irving Kahn’s firm keeps buying shares of 5 companies
Kahn Brothers (Trades, Portfolio) disclosed on Monday that the firm increased its holdings of 10 companies during the second quarter, including high-conviction trades in AT&T Inc. (NYSE:T), Bristol-Meyers Squibb Co. (NYSE:BMY), New York Community Bancorp Inc. (NYSE:NYCB), Assured Guaranty Ltd. (NYSE:AGO) and GlaxoSmithKline PLC (NYSE:GSK). Read more...
Bill Nygren Comments on Bristol-Myers Squibb Guru stock highlight
Bristol-Myers Squibb (NYSE:BMY) is a global biopharmaceutical company with leading franchises in oncology, immunoscience and cardiovascular drugs. Long-time shareholders may recall a successful Bristol-Myers Squibb investment that we sold in 2013. We got another opportunity to own this company during the past quarter when investors became fearful that a competing drug would take share in the cancer market. We believe these fears are overstated because cancer remains a dangerous disease that is difficult to treat. The company’s two most valuable drugs Opdivo and Yervoy should continue to grow revenue as they maintain effectiveness with new tumor types. Bristol Myers Squibb also has the most new molecular agents and the highest number of combinations of agents in trials. Moreover, the company’s R&D and marketing prowess also make it a desired partner for promising academic and small biotech innovators. Collectively, these assets should assure Bristol-Myers Squibb’s oncology leadership for many years. We believe intrinsic value is closer to the $70 level Read more...
Wall Street Low Friday Jabil fell on 4th-quarter earnings
The U.S. stock market extended losses on Friday, ahead of Trump's move to slap tariffs on up to $50 billion in Chinese goods. Read more...
2 Biotech Stocks Move Monday Nektar Therapeutics falls, Bluebird Bio rises
In Monday trading, shares of Nektar Therapeutics Inc. (NASDAQ:NKTR) plummeted after announcing the results of preliminary data from a phase 1/2 clinical trial, called PIVOT, which assesses the combination of NKTR-214 and Bristol-Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) in a range of cancers. The results were presented at the American Society of Clinical Oncology (ASCO) in Chicago. Read more...
Preliminary Data for NKTR-214 in Combination with Opdivo (nivolumab) for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at ASCO 2018
Vanguard Health Care Reduces Abbott, Bristol-Myers Positions Fund's largest sales of the 1st quarter
The Vanguard Health Care Fund (Trades, Portfolio) sold shares of the following stocks in the first quarter. Read more...
What Does Earnings Season Volatility Mean for American Airlines, Bristol-Myers Squibb, Chipotle Mexican Grill, MGM, and Universal Health Services?

Ratios

vs
industry
vs
history
PE Ratio 253.71
BMY's PE Ratio is ranked lower than
97% of the 557 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.77 vs. BMY: 253.71 )
Ranked among companies with meaningful PE Ratio only.
BMY' s PE Ratio Range Over the Past 10 Years
Min: 4.09  Med: 24.17 Max: 253.71
Current: 253.71
4.09
253.71
Forward PE Ratio 17.18
BMY's Forward PE Ratio is ranked higher than
64% of the 111 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.60 vs. BMY: 17.18 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 253.71
BMY's PE Ratio without NRI is ranked lower than
97% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.20 vs. BMY: 253.71 )
Ranked among companies with meaningful PE Ratio without NRI only.
BMY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.33  Med: 24.35 Max: 253.71
Current: 253.71
12.33
253.71
Price-to-Owner-Earnings 28.41
BMY's Price-to-Owner-Earnings is ranked higher than
58% of the 324 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 31.95 vs. BMY: 28.41 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BMY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.57  Med: 23.69 Max: 413.04
Current: 28.41
3.57
413.04
PB Ratio 8.07
BMY's PB Ratio is ranked lower than
87% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.64 vs. BMY: 8.07 )
Ranked among companies with meaningful PB Ratio only.
BMY' s PB Ratio Range Over the Past 10 Years
Min: 2.46  Med: 5.03 Max: 9.54
Current: 8.07
2.46
9.54
PS Ratio 4.63
BMY's PS Ratio is ranked lower than
63% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. BMY: 4.63 )
Ranked among companies with meaningful PS Ratio only.
BMY' s PS Ratio Range Over the Past 10 Years
Min: 1.62  Med: 3.69 Max: 7.25
Current: 4.63
1.62
7.25
Price-to-Free-Cash-Flow 24.33
BMY's Price-to-Free-Cash-Flow is ranked higher than
59% of the 298 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.84 vs. BMY: 24.33 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BMY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.41  Med: 19.74 Max: 375.94
Current: 24.33
7.41
375.94
Price-to-Operating-Cash-Flow 19.75
BMY's Price-to-Operating-Cash-Flow is ranked higher than
57% of the 392 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.00 vs. BMY: 19.75 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BMY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.93  Med: 14.68 Max: 97.02
Current: 19.75
6.93
97.02
EV-to-EBIT 23.08
BMY's EV-to-EBIT is ranked lower than
63% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.85 vs. BMY: 23.08 )
Ranked among companies with meaningful EV-to-EBIT only.
BMY' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.2  Med: 16.4 Max: 126.7
Current: 23.08
6.2
126.7
EV-to-EBITDA 19.95
BMY's EV-to-EBITDA is ranked lower than
62% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.24 vs. BMY: 19.95 )
Ranked among companies with meaningful EV-to-EBITDA only.
BMY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.5  Med: 14.2 Max: 57.3
Current: 19.95
5.5
57.3
EV-to-Revenue 4.67
BMY's EV-to-Revenue is ranked lower than
61% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.24 vs. BMY: 4.67 )
Ranked among companies with meaningful EV-to-Revenue only.
BMY' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6  Med: 3.9 Max: 7.4
Current: 4.67
1.6
7.4
PEG Ratio 17.62
BMY's PEG Ratio is ranked lower than
93% of the 317 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.93 vs. BMY: 17.62 )
Ranked among companies with meaningful PEG Ratio only.
BMY' s PEG Ratio Range Over the Past 10 Years
Min: 0.62  Med: 1.57 Max: 19.11
Current: 17.62
0.62
19.11
Shiller PE Ratio 26.83
BMY's Shiller PE Ratio is ranked higher than
62% of the 252 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.75 vs. BMY: 26.83 )
Ranked among companies with meaningful Shiller PE Ratio only.
BMY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.76  Med: 18.84 Max: 36.54
Current: 26.83
10.76
36.54
Current Ratio 1.40
BMY's Current Ratio is ranked lower than
73% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. BMY: 1.40 )
Ranked among companies with meaningful Current Ratio only.
BMY' s Current Ratio Range Over the Past 10 Years
Min: 1.13  Med: 1.63 Max: 2.32
Current: 1.4
1.13
2.32
Quick Ratio 1.28
BMY's Quick Ratio is ranked lower than
64% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.87 vs. BMY: 1.28 )
Ranked among companies with meaningful Quick Ratio only.
BMY' s Quick Ratio Range Over the Past 10 Years
Min: 0.93  Med: 1.39 Max: 2.06
Current: 1.28
0.93
2.06
Days Inventory 69.06
BMY's Days Inventory is ranked higher than
76% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 119.80 vs. BMY: 69.06 )
Ranked among companies with meaningful Days Inventory only.
BMY' s Days Inventory Range Over the Past 10 Years
Min: 69.06  Med: 116.62 Max: 141.93
Current: 69.06
69.06
141.93
Days Sales Outstanding 73.05
BMY's Days Sales Outstanding is ranked higher than
57% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 81.76 vs. BMY: 73.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
BMY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 35.38  Med: 48.27 Max: 76.37
Current: 73.05
35.38
76.37
Days Payable 105.93
BMY's Days Payable is ranked higher than
64% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.32 vs. BMY: 105.93 )
Ranked among companies with meaningful Days Payable only.
BMY' s Days Payable Range Over the Past 10 Years
Min: 105.39  Med: 141.65 Max: 230.86
Current: 105.93
105.39
230.86

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.61
BMY's Dividend Yield % is ranked higher than
76% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. BMY: 2.61 )
Ranked among companies with meaningful Dividend Yield % only.
BMY' s Dividend Yield % Range Over the Past 10 Years
Min: 1.99  Med: 3.71 Max: 7.07
Current: 2.61
1.99
7.07
Dividend Payout Ratio 6.63
BMY's Dividend Payout Ratio is ranked lower than
99% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. BMY: 6.63 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BMY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.58  Med: 0.92 Max: 6.63
Current: 6.63
0.58
6.63
3-Year Dividend Growth Rate 2.70
BMY's 3-Year Dividend Growth Rate is ranked lower than
64% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. BMY: 2.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
BMY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3 Max: 12.3
Current: 2.7
0
12.3
Forward Dividend Yield % 2.63
BMY's Forward Dividend Yield % is ranked higher than
74% of the 719 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.66 vs. BMY: 2.63 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.00
BMY's 5-Year Yield-on-Cost % is ranked higher than
69% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.12 vs. BMY: 3.00 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BMY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.28  Med: 4.26 Max: 8.12
Current: 3
2.28
8.12
3-Year Average Share Buyback Ratio 0.60
BMY's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 571 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -5.30 vs. BMY: 0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BMY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.6  Med: 0.6 Max: 5.2
Current: 0.6
-0.6
5.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 21.86
BMY's Price-to-Tangible-Book is ranked lower than
95% of the 749 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.33 vs. BMY: 21.86 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BMY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.16  Med: 12.2 Max: 53.46
Current: 21.86
4.16
53.46
Price-to-Intrinsic-Value-Projected-FCF 2.28
BMY's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
54% of the 374 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. BMY: 2.28 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BMY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.97  Med: 1.88 Max: 4.08
Current: 2.28
0.97
4.08
Price-to-Median-PS-Value 1.25
BMY's Price-to-Median-PS-Value is ranked lower than
71% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.94 vs. BMY: 1.25 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BMY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.52  Med: 0.82 Max: 2.33
Current: 1.25
0.52
2.33
Price-to-Peter-Lynch-Fair-Value 12.85
BMY's Price-to-Peter-Lynch-Fair-Value is ranked lower than
98% of the 212 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.41 vs. BMY: 12.85 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BMY' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.66  Med: 2.37 Max: 45.77
Current: 12.85
0.66
45.77
Price-to-Graham-Number 15.69
BMY's Price-to-Graham-Number is ranked lower than
99% of the 481 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. BMY: 15.69 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BMY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.53  Med: 3.2 Max: 15.69
Current: 15.69
1.53
15.69
Earnings Yield (Greenblatt) % 4.33
BMY's Earnings Yield (Greenblatt) % is ranked higher than
59% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.31 vs. BMY: 4.33 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BMY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.8  Med: 6.1 Max: 16.1
Current: 4.33
0.8
16.1
Forward Rate of Return (Yacktman) % 22.64
BMY's Forward Rate of Return (Yacktman) % is ranked higher than
95% of the 421 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.96 vs. BMY: 22.64 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BMY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -15  Med: 3 Max: 25.8
Current: 22.64
-15
25.8

More Statistics

Revenue (TTM) (Mil) $21,600.00
EPS (TTM) $ 0.24
Beta1.15
Volatility23.54%
52-Week Range $49.96 - 70.05
Shares Outstanding (Mil)1,631.88

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 22,291 23,616 25,094
EBIT (Mil $) 5,839 6,644 7,229
EBITDA (Mil $) 6,573 7,319 7,948
EPS ($) 2.75 3.81 4.28
EPS without NRI ($) 2.75 3.81 4.28
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.53%
Dividends per Share ($) 1.66 1.71 1.69

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

» More Articles for NYSE:BMY

Headlines

Articles On GuruFocus.com

More From Our Partners
Lilly (LLY) Hits 52-Week High, Can the Run Continue? Aug 17 2018 - ZACKS

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}